A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Ubenimex (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms LIBERTY2
- Sponsors Eiger BioPharmaceuticals, Inc.
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 03 Jan 2017 According to an Eiger BioPharmaceuticals media release, the first patient has received treatment with ubenimes in this extension trial.